J. Safra Asset Management’s AbbVie ABBV Stock Holding History

J. Safra Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Sell	5,519 -557	-9%	-$120K	0.06%	90
2026 Q1	$1.32M	Sell	6,076 -151	-2%	-$33.5K	0.07%	75
2025 Q4	$1.42M	Buy	6,227 +697	+13%	+$159K	0.07%	77
2025 Q3	$1.28M	Sell	5,530 -1,698	-23%	-$346K	0.08%	60
2025 Q2	$1.34M	Buy	7,228 +1,731	+31%	+$322K	0.09%	46
2025 Q1	$1.15M	Buy	5,497 +2,589	+89%	+$503K	0.09%	43
2024 Q4	$512K	Buy	2,908 +1,495	+106%	+$275K	0.04%	57
2024 Q3	$275K	Buy	1,413 +237	+20%	+$44.2K	0.03%	54
2024 Q2	$202K	Buy	1,176 +895	+319%	+$148K	0.02%	61
2024 Q1	$51.2K	Sell	281 -742	-73%	-$128K	0.01%	86
2023 Q4	$159K	Sell	1,023 -255	-20%	-$37.2K	0.02%	47
2023 Q3	$190K	Hold	1,278	–	–	0.03%	42
2023 Q2	$172K	Hold	1,278	–	–	0.02%	52
2023 Q1	$204K	Hold	1,278	–	–	0.03%	44
2022 Q4	$206K	Buy	+1,278	New	+$196K	0.04%	23
2022 Q1	–	Hold	0	–	–	–	89
2016 Q4	–	Sell	-507	Closed	-$32K	–	27
2016 Q3	$32K	Sell	507 -6,525	-93%	-$422K	0.06%	85
2016 Q2	$435K	Sell	7,032 -40,652	-85%	-$2.48M	0.71%	18
2016 Q1	$2.72M	Sell	47,684 -13,870	-23%	-$773K	2.22%	8
2015 Q4	$3.65M	Buy	+61,554	New	+$3.55M	2.8%	11

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

J. Safra Asset Management's ABBV Position: Q2 2026 in Review

J. Safra Asset Management reduced its AbbVie (ABBV) stake by 9.2% in Q2 2026, selling an estimated $120K and leaving 5,519 shares worth $1.39M. The position accounts for 0.06% of the portfolio, ranked #90.

J. Safra Asset Management first reported a position in ABBV in Q4 2015 and has held it in 19 quarters since. The position peaked at $3.65M in Q4 2015. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

J. Safra Asset Management held 5,519 shares of AbbVie worth $1.39M as of Q2 2026.
J. Safra Asset Management sold 557 AbbVie shares in Q2 2026, an estimated $120K.
AbbVie made up 0.06% of J. Safra Asset Management's portfolio in Q2 2026, its #90 holding.
J. Safra Asset Management first reported a position in AbbVie in Q4 2015 and has held it in 19 quarters since.
J. Safra Asset Management's AbbVie position peaked at $3.65M in Q4 2015.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.